BCAR4 Expression as a Predictive Biomarker for Endocrine Therapy Resistance in Breast Cancer.

Area of Science:

• Oncology
• Genetics
• Biomarkers

Background:

• Estrogen receptor-positive (ER+) breast cancer is a major cause of cancer death.
• Endocrine therapy resistance is a significant challenge in treating ER+ breast cancer.
• The BCAR4 gene's role in resistance and as a biomarker is explored.

Purpose of the Study:

• Investigate the association between BCAR4 gene expression and breast cancer patient outcomes.
• Determine if BCAR4 expression predicts resistance to endocrine therapies, including aromatase inhibitors (AIs).
• Assess BCAR4's clinical significance across different breast cancer subtypes.

Main Methods:

• Meta-analysis of 1743 patients across 6 independent cohorts.
• Examination of BCAR4 expression in relation to overall outcomes and PAM50 molecular subtypes.
• Investigation of BCAR4 expression and resistance to endocrine therapy and AIs.

Main Results:

• BCAR4 expression correlates with adverse outcomes and endocrine therapy resistance.
• BCAR4 expression is clinically significant in luminal A and B breast cancer subtypes.
• Elevated BCAR4 expression is associated with resistance to aromatase inhibitor (AI) treatment.

Conclusions:

• BCAR4 expression is linked to resistance to endocrine therapies, including newer treatments.
• Identifying patients with intrinsic hormone therapy resistance is crucial for effective treatment selection.
• Findings advance understanding of endocrine resistance and may guide future therapeutic strategies.